MedTrace Logo

Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease

NCT02462603 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-05-03

Study results available
· View outcomes & findings →

Summary

Open-label study with 30-day run-in phase and adaptive design component to include more participants if deemed appropriate by investigators.

Conditions

Interventions

DRUG

PTC-589

PTC-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.

Sponsors & Collaborators

  • Edison Pharmaceuticals Inc

    lead INDUSTRY

Principal Investigators

  • Matthew B Klein, MD FACS · Edison Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-17
Primary Completion
2019-01-08
Completion
2019-01-08
FDA Drug
Yes

Countries

  • United States
  • Germany
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462603 on ClinicalTrials.gov